Gene Therapy Casgevy denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Quantity Limits to Casgevy — and Why It Doesn't Apply Here

Casgevy is a single-administration gene therapy. By its clinical design, it is given once. A quantity-limit denial for Casgevy is therefore unusual and typically reflects either a billing or coding issue (e.g., the units billed do not match the expected dispensing format) or an administrative application of a blanket quantity-limit policy that was not designed for one-time gene therapies. Understanding which of these underlies the denial is the first step.

## Why This Denial Is Appealable

An adverse benefit determination based on a quantity limit that is clinically inapplicable — because the treatment is by definition a single administration — is a strong candidate for reversal. ACA §2719 and ERISA §503 require that plan decisions be based on accurate clinical and factual grounds. An IRO reviewing this denial would evaluate whether the quantity-limit rationale makes clinical sense for a one-time therapy.

## Federal Appeal Framework

• Immediate clarification call: Before filing a formal appeal, call Humana's PA/utilization management line and ask specifically what quantity limit was triggered and what the plan's quantity definition is for gene therapies. Sometimes this resolves the denial administratively.
• Internal appeal: Submit within the timeframe on the denial notice, with documentation that the treatment protocol involves a single administration.
• External review: If the internal appeal is denied, request IRO review. The approximately four-month external-review window begins from the final internal denial.
• Expedited review: Available if delay creates a health risk or disrupts a scheduled treatment protocol.

## Documentation to Gather

1. FDA prescribing label — dosing section: The label's dosing information describes the single-administration protocol. This directly contradicts any multi-dose quantity-limit rationale. 2. Treatment center protocol: Documentation from the authorized treatment center confirming the one-time administration plan. 3. Claim and billing review: Have the specialty pharmacy or treatment center verify that the units and procedure codes submitted match the expected single-course format for gene therapy. 4. Prescriber letter: A letter from your hematologist explaining that the FDA-approved protocol involves a single treatment course and that the quantity-limit policy does not apply as written. 5. Humana policy text: Obtain the specific quantity-limit policy Humana cited and analyze whether its language contemplates gene therapies at all.

## Criteria-Mapping Strategy

The appeal argument here is structural: the quantity-limit policy was designed for recurring prescriptions and does not map onto a single-administration biologic. Document this mismatch explicitly — quote the policy's language, quote the prescribing label's single-administration protocol, and ask Humana to identify which clinical criterion justifies applying a quantity limit to a one-time treatment. The burden shifts to the plan to explain the rationale.